Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia

Published:2008 Issue:3 Volume:83 Page:185-188
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Zhang Wang-Gang,Wang Fang-Xia,Chen Yin-Xia,Cao Xin-Mei,He Ai-Li,Liu Jie,Ma Xiao-Rong,Zhao Wan-Hong,Liu Su-Hu,Wang Jian-Li

Publisher

Wiley

Subject

Hematology

Reference34 articles.

1. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

2. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients

3. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin–induced cytotoxicity

4. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed;Med;2024-08

2. Homoharringtonine promotes heart allograft acceptance by enhancing regulatory T cells induction in a mouse model;Chinese Medical Journal;2023-11-14

3. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study;Annals of Hematology;2023-09-18

4. Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience;Hematology;2023-05-16

5. Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study;Blood Advances;2021-03-31